Calidi
CLDI
Calidi (CLDI) news
Recent news
Calidi Biotherapeutics announces $1.2 million registered direct offering
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has announced a $1.2 million registered direct offering to support its ongoing development of targeted genetic medicines and advance its pipeline toward clinical trials. The offering, which is part of the company’s broader capital-raising strategy,…
AInvest Wire · Sep 17, 2026Calidi: reverse stock split, expected to begin trading on a 1-for-16 split adjusted basis on July 31, 2026
AInvest Wire · Jul 20, 2026Calidi Biotherapeutics appoints former Genentech/Roche and Celgene executive Corsee Sanders, Ph.D., to board of directors
AInvest Wire · Jun 23, 2026Calidi Biotherapeutics - targets CLD-401 regulatory submission by year-end, first-in-human trial in early 2027
AInvest Wire · Jun 16, 2026Calidi Biotherapeutics receives positive pre-IND feedback from US FDA for CLD-401 indicating agreement on its current development strategy as it advances towards a first-in-human study
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.